U.S. Hospitality Stock News

Arcutis Biotherapeutics (ARQT) has drawn fresh investor attention after reporting strong revenue growth tied to its dermatology pipeline, with lead product ZORYVE playing a central role even as the company continues to post operating losses. See our latest analysis for Arcutis Biotherapeutics. The recent dermatology update comes after a strong 90 day share price return of 49.03% and a 1 year total shareholder return of 95.68%. This suggests momentum has been building around Arcutis...

In recent days, NOV has attracted renewed attention from Wall Street as multiple research firms updated their views on the company and reaffirmed their outlooks based on recent operational and industry developments. This cluster of analyst revisions highlights a shift in how the market is interpreting NOV’s position in the energy equipment landscape and its potential to execute on current opportunities and challenges. We’ll now explore how this improving analyst sentiment shapes NOV’s...

AMC Entertainment Holdings (AMC) is back in focus after its shares hit an all time low, even as the company reported its strongest pre Christmas weekend box office since 2021 on Avatar: Fire and Ash. See our latest analysis for AMC Entertainment Holdings. That mix of record pre Christmas box office and a new all time low share price has come after a sharp reset in expectations, with a 30 day share price return of 36.4% and a 1 year total shareholder return decline of 63.3%, suggesting...

AGCO’s AE50 awards and what they might mean for the stock AGCO (AGCO) recently received seven 2026 AE50 awards from the American Society of Agricultural and Biological Engineers, spotlighting its agricultural machinery and technology across Fendt, Massey Ferguson and PTx brands. For investors, this kind of industry recognition can be a useful prompt to reassess how AGCO’s product portfolio, financial profile and current valuation align with expectations for future demand and...

Immuneering (IMRX) is back on traders’ screens after releasing updated Phase 2a data for atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing higher overall survival and response metrics than standard benchmarks. See our latest analysis for Immuneering. The updated atebimetinib data arrive after a tough recent stretch, with the share price at US$4.73 and a 1 day share price return of 43.22% decline. However, a 1 year total shareholder return of 136.5%...

If you are wondering whether Hewlett Packard Enterprise at around US$22 is offering good value today, you are in the right place to get a clear, valuation focused view. The stock has had a mixed run, with a 7 day return of an 8.3% decline and a 30 day return of an 11.1% decline, while the longer term picture shows a 1 year return of 2.6%, around 46.8% over 3 years and about 104.5% over 5 years. Recently, Hewlett Packard Enterprise has been in the news for its ongoing role as a key...

In recent days, Hasbro has drawn fresh attention as analysts highlighted the company’s consistent earnings outperformance, favorable earnings estimate revisions, and growing enthusiasm around its branded product launches and digital initiatives. A lesser-known angle is how the company’s history of licensing missteps and its current adult-collector focus illustrate the importance of disciplined IP management and brand execution for its long-term outlook. We’ll now examine how this renewed...

RLI (RLI) is back on investors’ radar after recent trading left the shares with a 1 day return of 2.1%, but negative moves over the past week, month and past 3 months. See our latest analysis for RLI. That one-day share price gain comes after a softer patch, with a year-to-date share price return of a 2.4% decline and a one-year total shareholder return of a 17.2% decline. This suggests momentum has faded recently despite a 43.1% total shareholder return over five years. If RLI’s recent...

Catalyst Pharmaceuticals, a commercial-stage rare disease drugmaker, was recently ranked 11th on Forbes’ 2026 list of America’s Most Successful Small-Cap Companies, reflecting external recognition of its execution and profile among peers. This accolade adds an extra layer of validation to Catalyst’s rare disease-focused model at a time when investors are closely watching its product concentration, patent outlook, and business development efforts. We’ll now explore how this Forbes...

Lazard (LAZ) has attracted investor attention after recent moves in its share price, with the stock closing at US$50.71 and showing mixed returns over the past week, month, and past 3 months. See our latest analysis for Lazard. The recent move to US$50.71 comes after a 4.43% 7 day share price return and a 5.95% 3 month share price return, while the 1 year total shareholder return of 5.72% sits against a much stronger 3 year total shareholder return of 54.79%. This suggests momentum has been...

If you are wondering whether BlackRock's current share price still represents good value, you are not alone. This article is here to unpack that question clearly and calmly. With the stock last closing at US$1,087.92 and showing returns of 1.6% over 7 days, 1.6% over 30 days, 0.3% year to date, 12.6% over 1 year, 55.1% over 3 years, and 65.0% over 5 years, many investors are asking what those numbers suggest about future risk and reward. Recent headlines around BlackRock have kept the...

Consolidated Edison (ED) is back in focus after agreeing to sell its 6.6% Mountain Valley Pipeline stake to Ares Management for US$357.5 million, alongside an expected multi year New York rate plan approval. See our latest analysis for Consolidated Edison. The planned rate plan approval and pipeline exit come as Consolidated Edison’s share price has moved only modestly in the short term, with a 1 month share price return of 4.6% but a 90 day share price return of a 2.2% decline, while the 1...

Wondering if Jones Lang LaSalle at around US$346 a share is still good value, or if the easy money has already been made? This article will walk you through what the numbers actually say about the stock's price tag. The share price has recently closed at US$346.28, with returns of 2.9% over 7 days, 6.5% over 30 days, 3.1% year to date, 39.7% over 1 year, 98.5% over 3 years and 132.3% over 5 years. This naturally raises questions about how much upside or risk might be priced in today. Recent...

Recently, Zacks highlighted Patria Investments as a strong growth stock, citing its favorable Growth Score, positive earnings estimate revisions, and an expected 21.8% EPS increase this year versus the broader industry. This endorsement also pointed to Patria’s comparatively stronger cash flow trends, suggesting its business model may be gaining traction relative to peers. Now we’ll examine how this upbeat earnings outlook and cash flow commentary could reshape Patria Investments’ broader...

Align Technology has already announced it will release its fourth-quarter and full-year 2025 results on 4 February 2026 after the market close, followed by a webcasted conference call reviewing performance in its clear aligner and digital dentistry businesses. This upcoming earnings update has drawn attention because it follows earlier guidance revisions showing year-over-year Clear Aligner volume growth and analysts’ expectations for higher profitability. Next, we’ll examine how the raised...

In the third quarter of 2025, TimesSquare Capital Management highlighted Casella Waste Systems in its investor letter, noting that while revenue exceeded expectations, earnings were pressured by slower integration of acquired territories and rollout of a new enterprise resource planning system. The investor’s decision to increase its Casella holdings, despite these temporary operational setbacks, underscores confidence that integration progress and ERP benefits could enhance margins over...

Flutter Entertainment (FLUT) has drawn fresh investor attention after disclosing that Candle Lake Limited has crossed the 15% voting rights threshold through equity swap agreements, a shift in ownership that can influence how you view the stock. See our latest analysis for Flutter Entertainment. The Candle Lake move lands at a time when Flutter’s share price, now at $217.36, has seen a 2.8% 1 day share price return and a 10.3% 3 month share price decline. The 3 year total shareholder return...

Futu Holdings (FUTU) is back in focus after strong quarterly earnings and a 9.01% move higher, with investors weighing its high leverage against its solid cash position and recent business adjustments. See our latest analysis for Futu Holdings. That earnings driven jump sits within a mixed picture, with a 7 day share price return of 9.66% and a 90 day share price return of 16.48%. Meanwhile, the 1 year total shareholder return of 132.57% points to strong momentum that has built over time...

Wondering if Dell Technologies at around US$118.50 is still good value or if most of the opportunity is already priced in? This article is going to help you size up what you are really paying for the stock. The share price is down 5.9% over the last week and 14.3% over the last month, while the 1 year return is 1.1% and the 3 year return is 216.0%. This hints at a very different experience depending on when you came in. Recent attention on large technology names and ongoing discussion about...

Pegasystems recently saw pressure on its stock after investors reassessed rate-sensitive software names and a company officer filed to sell up to 4,000 shares. This combination of sector-wide repricing and insider activity has sharpened attention on how upcoming economic data and earnings could influence sentiment toward Pegasystems. We’ll now explore how the officer’s planned share sale and shifting rate expectations may affect Pegasystems’ existing investment narrative. Rare earth metals...

Commvault Systems (CVLT) is drawing fresh attention as investors focus on its growing data protection and cyber resilience offerings, including an expanding SaaS lineup and deeper ties with major cloud providers. See our latest analysis for Commvault Systems. At a share price of US$124.14, Commvault’s 90-day share price return of a 27.06% decline contrasts with a 1-year total shareholder return of a 21.33% decline and a 3-year total shareholder return of a 126.04% gain. This suggests longer...

Analyst downgrade puts fresh spotlight on Nuvation Bio A recent UBS downgrade of Nuvation Bio (NUVB) to a hold rating has pulled fresh attention to the stock, prompting investors to reassess how they view its oncology pipeline and current valuation. See our latest analysis for Nuvation Bio. The downgrade lands after a sharp run, with a 90 day share price return of 125.94% and a 1 year total shareholder return of 180.73%. The latest 1 day move was a 4.41% decline, suggesting momentum may be...

In early January 2026, Xeris Biopharma Holdings raised its full-year 2025 revenue guidance to approximately US$292 million, above its prior US$285 million–US$290 million range, citing record fourth-quarter and full-year revenue performance. The company also reported stronger-than-expected commercial momentum for Recorlev and recent patent additions, which together reinforce management’s confidence in its long-term growth ambitions. Next, we’ll explore how this upgraded revenue outlook and...

If you are wondering whether Comerica's share price still offers value after a strong run, this review will help you separate sentiment from what the numbers suggest. Comerica's stock last closed at US$92.56, with returns of 6.5% over 7 days, 10.5% over 30 days, 4.4% year to date, 55.1% over 1 year, 57.3% over 3 years and 76.8% over 5 years. Recent market attention on U.S. regional banks has kept Comerica in focus, as investors reassess how interest rate expectations and credit conditions...